Mounjaro for type 2 diabetes vs Mounjaro for weight loss: same drug, different conversation

The two licences

Mounjaro for type 2 diabetes was licensed by the MHRA in 2022 and approved for NHS use by NICE under TA924 in 2023. The indication is adults with T2D where HbA1c is not adequately controlled despite first- and second-line therapy. In practice, it sits alongside or replaces a sulphonylurea, SGLT2 inhibitor or basal insulin as third-line or later treatment.

Mounjaro for weight loss was approved by NICE under TA1026 in 2024. The indication is adults with BMI ≥35 (or ≥32.5 in some ethnic minority groups) with at least one weight-related comorbidity, prescribed within a specialist weight management service.

The active ingredient is identical. The pens are identical. The differences sit in eligibility, prescribing setting and clinical conversation.

NICE TA924 vs NICE TA1026

The two pathways diverge in important ways:

• Prescribing setting. TA924 (T2D) can be prescribed by GPs under shared care arrangements or directly by diabetes specialists. TA1026 (weight loss) is restricted to Tier 3 specialist weight management services on the NHS — see our Tier 3 waiting list guide.
• Eligibility. TA924 requires HbA1c above threshold and prior treatment failure. TA1026 requires BMI threshold and comorbidity. Both routes use the same product but apply different gateways.
• Funding. TA924 is funded under diabetes commissioning. TA1026 is funded under obesity/weight management commissioning. The same medication accessed via the T2D pathway is sometimes available faster than via the weight loss pathway, because diabetes is a more established commissioning area.
• Review cadence. T2D treatment is reviewed on HbA1c response (typically at 6 months). Weight loss treatment is reviewed on percentage weight loss (typically 5% at 6 months as a continuation threshold).

Dosing — looks the same, often plays out differently

The titration schedule is identical: 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, up to a maximum of 15 mg weekly. In practice:

• T2D patients often plateau at 5–10 mg. The HbA1c benefit at 10 mg is substantial and many do not need to push higher. Going to 15 mg in T2D is reserved for patients where both glucose and weight need further improvement.
• Weight loss patients typically reach higher doses. The full 15 mg is more often used to maximise sustained weight loss.

Both groups follow the same nausea and side-effect timeline — see the GLP-1 side effects timeline.

The HbA1c benefit

The SURPASS clinical trials demonstrated the magnitude of glucose-lowering with tirzepatide:

• At 5 mg weekly: HbA1c reduction of approximately 1.9% from a baseline of ~8.3%.
• At 10 mg weekly: HbA1c reduction of approximately 2.0–2.4%.
• At 15 mg weekly: HbA1c reduction of approximately 2.4–2.6%.

These figures are larger than anything previously available outside intensive insulin regimes. For comparison, metformin typically reduces HbA1c by 1.0–1.5%, semaglutide (Wegovy/Ozempic) by 1.5–2.0%, sulphonylureas by 1.0–1.5%. For many patients, tirzepatide at 10 mg moves them from inadequately controlled to within target HbA1c, with substantial weight loss as a bonus.

Concurrent diabetes medication considerations

Mounjaro is typically added on top of metformin (which most T2D patients continue indefinitely). The interactions:

• Metformin — continue. Note that combined metformin + tirzepatide markedly increases B12 deficiency risk — we screen B12 at baseline and annually. See metformin and B12 deficiency.
• Sulphonylureas (gliclazide, glimepiride) — hypoglycaemia risk rises when added. Many patients reduce or stop their sulphonylurea after a few weeks of tirzepatide.
• SGLT2 inhibitors (empagliflozin, dapagliflozin) — generally continue; complementary mechanism. Watch for volume depletion and dehydration if also losing weight rapidly.
• Basal insulin — typically the insulin dose is reduced by 20–30% when tirzepatide is started, with further adjustment over the following weeks based on glucose monitoring.

Patients with both indications

If you have type 2 diabetes and meet the BMI threshold for weight loss prescribing, you are in the strongest position to benefit. You see HbA1c reduction and substantial weight loss simultaneously. Weight loss often improves T2D dramatically — some patients reduce or come off other diabetes medications altogether.

For these patients, the practical question is which NHS pathway to enter. The T2D pathway (TA924) is generally faster on the NHS because it sits within primary care diabetes commissioning. The weight loss pathway (TA1026) sits within Tier 3 commissioning, which is slower (see our Tier 3 guide). If you have T2D and obesity, ask your GP to consider the T2D pathway first.

The insurance and cost question

NHS T2D prescriptions are free at the point of use (subject to prescription charge, or free in Wales/Scotland/Northern Ireland and for exempt categories in England). NHS weight loss prescriptions via Tier 3 are also free. Private prescriptions via Trafford Clinic and other pharmacist-led services are paid out-of-pocket. See our pricing page for current figures.

How we approach the decision

Haroon will take a structured history at the first appointment: do you have T2D; what is your current HbA1c; what is your BMI; what other medications are you on; what is your ethnic background (relevant for the South Asian thresholds in NICE CG189). Based on that, we map the route. We run a pre-Mounjaro baseline blood panel and start at 2.5 mg weekly with weekly support.

For comparison with semaglutide, see Mounjaro vs Wegovy. To understand what to do if you stop the medication, see what happens when you stop Mounjaro. For monitoring blood results, see reading blood test results.

Local pages: Manchester, Old Trafford, Rusholme, Sale and Altrincham. For diabetic patients we can also arrange follow-up blood tests.